A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
about
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meSecretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancerPertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Antibodies to watch in 2010The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for huPooled analysis of cardiac safety in patients with cancer treated with pertuzumab.A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancerA critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancerSignalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.Level of evidence for therapeutic drug monitoring of taxanes.Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.Pertuzumab: new hope for patients with HER2-positive breast cancer.HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology.Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.Pertuzumab for the treatment of metastatic breast cancer.Pertuzumab for the treatment of breast cancer.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Pertuzumab in gastrointestinal cancer.Pertuzumab for the treatment of breast cancer: a safety review.Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
P2860
Q28083123-3CF77275-3F91-4B6A-BC3B-43A344697F8FQ30376023-C037B163-CE97-405C-BCDB-A069BD7B4812Q30497364-8BCC1D58-0550-4D32-ADFE-571A89CE823FQ33618685-E5C246B4-C997-4188-9890-0C18A2267D4DQ33680109-0DDEB947-2B3C-46B8-9857-EC2E6D4789EEQ33688243-57DF7945-0EAA-407F-8F72-6FDECFB59681Q33829742-B9B5162C-F329-425F-A77A-E393A41A0755Q33930241-92F78062-9F6C-4C05-A383-8E443FADC845Q34051972-60D53203-FDCD-4884-9A0C-5597AEEAC4FEQ35682599-53724730-1A28-4BF9-BF7A-3ACE4B2FF0E0Q36730394-0950C9F1-8C7F-4397-9C29-6F22199BC006Q37205749-C3407313-B162-4C32-855A-2A2A3AC42BC9Q37575815-8F801C92-AE22-4F8E-80CD-2C9CBE5148BAQ37636774-336F6515-E7FA-47E8-B4D9-1BDFF0E4EE5BQ37788732-0EA51FE3-0E1B-42DD-9E21-059882D8FF88Q37982433-83A271CC-7932-4D3D-BBAB-7BF5F4F21F8CQ38036549-7D2E3907-F15E-4114-8547-B4C2D4413ED2Q38089883-B59BA5E5-08AA-444B-8931-7B393674E5E8Q38093224-2877A22A-8054-4129-AE4B-0919D5A1E797Q38123762-43BD50E9-F2AE-4AB9-8B6E-C0E4C4824741Q38132047-5BB52E39-05A7-4218-B6F5-0AB5E9E67116Q38132237-E324760A-84DD-487D-A63B-927C5D9BA7CDQ38219674-AAE7A8C5-9027-43E3-96A3-CC668AEEF23AQ38286163-D940C3A7-414C-46DC-A9E0-89D355743F1CQ38373931-F25AB29E-F0C7-4992-8BCB-E359D7A6F787Q38573858-BBDDB80C-5524-4C52-85E7-BD71D84819AAQ38653309-572DD3AE-5F0F-4C9F-B692-C42DEF1F0E5CQ38776876-04933DF9-2411-4151-92C6-D97FC7996544Q46216597-2556F1E4-65AD-4F22-97A6-A22E403E0919Q48332395-256A93C1-0826-4062-AA72-E0E51A651E9C
P2860
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@ast
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@en
type
label
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@ast
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@en
prefLabel
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@ast
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@en
P2093
P2860
P356
P1476
A phase Ib study of pertuzumab ...... s with advanced solid tumours.
@en
P2093
G Zugmaier
J S de Bono
M de Jonge
S P Blagden
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604043
P407
P577
2007-11-13T00:00:00Z
P5875
P6179
1033972314